Can Nanoparticles Give An Old Iron Chelator A New Life? — Development Of Targeted Polymeric Nanoparticles With Long Half-lives To Treat Iron Overload Diseases
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Iron loading disorders (such as thalassaemia) represent an important class of human disease. As part of the treatment for these diseases, the iron needs to be removed and this is often done using iron-binding drugs known as iron chelators. Current chelators are not ideal due to side effects or onerous delivery methods. The goal of this project is to use nanotechnology to develop more effective ways of delivering chelators to improve their effectiveness and reduce toxicity.
Patient Tailored Anti-tumour T Cells To Prevent Relapse In Patients With Acute Myeloid Leukaemia Undergoing Allogeneic Haemopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$190,445.00
Summary
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.
To Determine Whether Myc-driven Transformation In Haematopoietic Cell Lineages Is Dependent On High-levels Of Myc Protein Expression.
Funder
National Health and Medical Research Council
Funding Amount
$371,896.00
Summary
Myc is an essential cellular protein but is also a common drive of cancer in multiple tissues. In blood cancers Myc is frequently overexpressed. In contrast, Myc is rarely overexpressed in early stage solid cancers, although often elevated levels at later stages. We will employ unique models of cancer in which Myc can be activated at different set levels at different times during blood cell development to address what the specific contributions of different levels of Myc are in the evolution of ....Myc is an essential cellular protein but is also a common drive of cancer in multiple tissues. In blood cancers Myc is frequently overexpressed. In contrast, Myc is rarely overexpressed in early stage solid cancers, although often elevated levels at later stages. We will employ unique models of cancer in which Myc can be activated at different set levels at different times during blood cell development to address what the specific contributions of different levels of Myc are in the evolution of blood cancers.Read moreRead less
Interactions Between Aberrant Transcriptional Programs And Methylation In Primary Myelodysplasia And Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Impaired development of blood stem cells leads to haematological disease such as leukaemia. State of the art next-generation sequencing and bioinformatics identified molecular pathways essential for normal blood development and a core set of these genes repressed in leukaemia. Understanding the mechanism by which these genes are re-activated by the non-specific drug azacitidine contributes to the development of new therapeutics with increased efficiency and reduced side effects.
Understanding How Second Primary Malignancies Arise Following Multiple Myeloma Therapy
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
Multiple myeloma is a cancer of white blood cells. Chemotherapy and new drugs that target cancer cells are the most effective therapies for multiple myeloma. However, these drugs also increase the chance of developing a secondary cancer that is different to the initial cancer. Little is known about how these cancers arise. I aim to find out how current therapies cause secondary cancers; with the hope of finding alternative therapies for multiple myeloma that do not cause secondary cancers.
Kinetics, Mechanism And Engraftment Of In Vitro Generated T Cell Precursors As A Strategy To Enhance Thymic Rejuvenation Following Allogeneic Hematopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$403,324.00
Summary
Immune regeneration - following standard cancer therapies such as chemotherapy and radiation-therapy for hematopoietic (blood) stem cell transplant (HSCT) - is one of the most significant unmet clinical challenges today. This research will focus on using “off the shelf” precursor T cells to improve immune reconstitution following HSCT, thereby significantly reducing the incidence of morbidity and mortality following transplantation.
Investigating The Gene And Gene Expression Differences In The Cells That Drive Leukemia Development And Relapse In Children With AML
Funder
National Health and Medical Research Council
Funding Amount
$388,612.00
Summary
Current treatments for AML are initially effective at killing the majority of leukemic cells, but the disease often comes back (relapses) due to rare cells that escape treatment and can regenerate the cancer (called leukemic stem cells or LSC for short). This project aims to determine if an individual patient has one, or many kinds of LSC and which kind of LSC is most likely to cause relapse. We believe that this knowledge will lead to new treatments that can target the cells that cause relapse.
Balance disorders are very common, but particularly in those conditions that involve the brain 'balance centres' are often difficult for doctors to diagnose. When diseases are difficult to diagnose, then recommending helpful treatment is particularly challenging. We will use a group of specialized tests to better understand these balance conditions in order to help patients receive accurate diagnoses and therefore, better treatment.